NCT06140758View on ClinicalTrials.gov

Evaluation of the Anticaries Efficacy of Dentifrice Formulations Using an In-situ Model

NACompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

December 11, 2023

Study Completion Date

December 11, 2023

Conditions

Caries

Interventions

DRUG

Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice

Each subject will use this product during one of the six treatment periods in the crossover study design.

DRUG

Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice

Each subject will use this product during one of the six treatment periods in the crossover study design.

DRUG

Toms of Maine 0 ppm Fluoride Dentifrice

Each subject will use this product during one of the six treatment periods in the crossover study design.

DRUG

Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice

Each subject will use this product during one of the six treatment periods in the crossover study design.

DRUG

1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice

Each subject will use this product during one of the six treatment periods in the crossover study design.

DRUG

1100 ppm (0.454% Stannous fluoride) Dentifrice

Each subject will use this product during one of the six treatment periods in the crossover study design.

Trial Locations (1)

Unknown

University of Melbourne, Melbourne

All Listed Sponsors

lead

Procter and Gamble

INDUSTRY